CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.82B, above the global median of $1.15B
- PositionOperating margin is 49%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.82BUSDvs all stocks (USD)
Trailing P/E
49.20xvs Biotechnology peers
Revenue (TTM)
2.18BUSDvs all stocks (USD)
Profit Margin
2.98%vs Biotechnology peers
Beta
0.2020xvs all stocks
52-Week Change
29.28%vs all stocks
Market Capitalization
1.82BUSDvs all stocks (USD)
Enterprise Value
2.21BUSDvs all stocks (USD)
Trailing P/E
49.20xvs Biotechnology peers
Forward P/E
7.03xvs Biotechnology peers
PEG Ratio
-0.2920xvs Biotechnology peers
Price to Sales (TTM)
0.8324xvs Biotechnology peers
Price to Book (MRQ)
1.21xvs Biotechnology peers
Enterprise to Revenue
1.01xvs Biotechnology peers
Enterprise to EBITDA
47.89xvs Biotechnology peers
Gross Margin
85.12%vs Biotechnology peers
Profit Margin
2.98%vs Biotechnology peers
Operating Margin
49.05%vs Biotechnology peers
Return on Assets (TTM)
0.02%vs Biotechnology peers
Return on Equity (TTM)
4.91%vs Biotechnology peers
Revenue (TTM)
2.18BUSDvs all stocks (USD)
Revenue per Share (TTM)
21.41USDUpdated Jul 19, 2026Quarterly Revenue Growth
-1.90%vs Biotechnology peers
Gross Profit (TTM)
470.80MUSDvs all stocks (USD)
EBITDA (TTM)
46.18MUSDvs all stocks (USD)
Net Income (TTM)
65.06MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.89%vs Biotechnology peers
Operating Cash Flow (TTM)
175.28MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
204.78MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.20BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
839.61MUSDFY2025 · Dec 31, 2025Gross Profit
1.36BUSDFY2025 · Dec 31, 2025Operating Income
-657.77MUSDvs all stocks (USD)
Pre-tax Income
-702.23MUSDFY2025 · Dec 31, 2025Income Tax Expense
11.19MUSDFY2025 · Dec 31, 2025Net Income
-713.41MUSDFY2025 · Dec 31, 2025EBIT
-664.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-578.50MUSDFY2025 · Dec 31, 2025Research & Development
1.52BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
491.72MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
36.69MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
38.14MUSDFY2025 · Dec 31, 2025EPS (Basic)
-7.13USDFY2025 · Dec 31, 2025EPS (Diluted)
-7.13USDFY2025 · Dec 31, 2025Basic Shares Outstanding
100.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
100.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-713.41MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-475.71MUSDFY2025 · Dec 31, 2025Free Cash Flow
-577.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
814.41MUSDFY2025 · Dec 31, 2025Income Tax Paid
37.63MUSDFY2025 · Dec 31, 2025Interest Paid
14.91MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-713.41MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
44.52MUSDFY2025 · Dec 31, 2025Stock-based Compensation
123.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
70.59MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
203.75MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
104.27MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-308.83MUSDFY2025 · Dec 31, 2025Capital Expenditures
-101.97MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-7.88MUSDFY2025 · Dec 31, 2025Net Acquisitions
174.09MUSDFY2025 · Dec 31, 2025Purchase of Investments
-290.48MUSDFY2025 · Dec 31, 2025Sale of Investments
295.87MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
77.52MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-162.59MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-25.01MUSDFY2025 · Dec 31, 2025Other Financing Charges
-19.45MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-187.05MUSDFY2025 · Dec 31, 2025Shares Outstanding
105.57MSharesUpdated Jul 19, 2026Float Shares
94.61MSharesUpdated Jul 19, 2026Shares Short
28.73MSharesUpdated Jul 19, 2026Short Ratio
7.43daysvs all stocks
Short % of Shares Outstanding
32.62%vs all stocks
% Held by Insiders
4.21%vs all stocks
% Held by Institutions
99.60%vs all stocks
Total Cash (MRQ)
653.19MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.19USDUpdated Jul 19, 2026Total Debt (MRQ)
1.05BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6957xvs Biotechnology peers
Current Ratio (MRQ)
4.63xvs Biotechnology peers
Book Value per Share (MRQ)
14.26USDUpdated Jul 19, 2026Total Assets
3.35BUSDvs all stocks (USD)
Total Current Assets
2.54BUSDFY2025 · Dec 31, 2025Total Liabilities
2.21BUSDFY2025 · Dec 31, 2025Total Non-current Assets
811.76MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.11BUSDFY2025 · Dec 31, 2025Total Current Liabilities
1.10BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
801.28MUSDFY2025 · Dec 31, 2025Other Short-term Investments
138.37MUSDFY2025 · Dec 31, 2025Accounts Receivable
398.23MUSDFY2025 · Dec 31, 2025Inventory
914.74MUSDFY2025 · Dec 31, 2025Accounts Payable
280.84MUSDFY2025 · Dec 31, 2025Short-term Debt
11.39MUSDFY2025 · Dec 31, 2025Deferred Revenue
443.40MUSDFY2025 · Dec 31, 2025Long-term Debt
1.03BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.53MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-4.88BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.14BUSDvs all stocks (USD)
Treasury Stock
25.26MUSDFY2025 · Dec 31, 202552-Week Low
10.42USDUpdated Jul 19, 202652-Week High
25.32USDUpdated Jul 19, 202652-Week Change
29.28%vs all stocks
Beta
0.2020xvs all stocks
50-Day MA
17.61USDUpdated Jul 19, 2026200-Day MA
19.73USDUpdated Jul 19, 2026Avg 10-Day Volume
2.90MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.56MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.3500USDUpdated Jul 19, 2026Other Income / Expense
-43.00MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 49%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.49Industry median: -0.24Industry P95: 0.38Peers compared: 197
Price-to-book is 1.21×, lower than 95% of its Biotechnology peers (median 5.36×)Notable
Price-to-book: 1.21Industry median: 5.36Industry P5: 1.40Peers compared: 197
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.85Profit Margin: 0.03
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.63Altman Z-Score: -1.03
Financial Health
Altman Z-Score -1.03: distress zoneCritical
Altman Z-Score: -1.03
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.82B, above the global median of $1.15BNotable
Market cap (USD): 1,818,022,542Global Median: 1,146,734,693.424
Revenue is $2.18B, above the global median of $520.53MNotable
Revenue (USD): 2,184,184,064Global Median: 520,528,949.311
Levered free cash flow is $204.78M, above the global median of $16.24MNotable
Levered free cash flow (USD): 204,779,632Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bicara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ani Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Bakkt Holdings, Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
BALLARD POWER SYSTEMS INC Common Stock
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Bitdeer Technologies Group
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated